Integration of cell line and process development to overcome the challenge of a difficult to express protein

This case study addresses the difficulty in achieving high level expression and production of a small, very positively charged recombinant protein. The novel challenges with this protein include the protein's adherence to the cell surface and its inhibitory effects on Chinese hamster ovary (CHO) cell growth. To overcome these challenges, we utilized a multi‐prong approach. We identified dextran sulfate as a way to simultaneously extract the protein from the cell surface and boost cellular productivity. In addition, host cells were adapted to grow in the presence of this protein to improve growth and production characteristics. To achieve an increase in productivity, new cell lines from three different CHO host lines were created and evaluated in parallel with new process development workflows. Instead of a traditional screen of only four to six cell lines in bioreactors, over 130 cell lines were screened by utilization of 15 mL automated bioreactors (AMBR) in an optimal production process specifically developed for this protein. Using the automation, far less manual intervention is required than in traditional bench‐top bioreactors, and much more control is achieved than typical plate or shake flask based screens. By utilizing an integrated cell line and process development incorporating medium optimized for this protein, we were able to increase titer more than 10‐fold while obtaining desirable product quality. Finally, Monte Carlo simulations were performed to predict the optimal number of cell lines to screen in future cell line development work with the goal of systematically increasing titer through enhanced cell line screening. © 2015 American Institute of Chemical Engineers Biotechnol. Prog., 31:1201–1211, 2015

[1]  A. F. Paes Leme,et al.  Generation of a Chinese Hamster Ovary Cell Line Producing Recombinant Human Glucocerebrosidase , 2012, Journal of biomedicine & biotechnology.

[2]  H. Prentice,et al.  Improving Performance of Mammalian Cells in Fed‐Batch Processes through “Bioreactor Evolution” , 2007, Biotechnology progress.

[3]  E. Käs,et al.  Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells , 1983, Cell.

[4]  R. Schimke,et al.  Gene amplification in a single cell cycle in Chinese hamster ovary cells. , 1984, The Journal of biological chemistry.

[5]  A. Otte,et al.  A novel, high stringency selection system allows screening of few clones for high protein expression. , 2007, Journal of biotechnology.

[6]  Y. Kozutsumi,et al.  The Molecular Basis for the Absence ofN-Glycolylneuraminic Acid in Humans* , 1998, The Journal of Biological Chemistry.

[7]  Takeshi Omasa,et al.  Cell engineering and cultivation of chinese hamster ovary (CHO) cells. , 2010, Current pharmaceutical biotechnology.

[8]  L. Chasin,et al.  Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Estes,et al.  High‐throughput ion exchange purification of positively charged recombinant protein in the presence of negatively charged dextran sulfate , 2014, Biotechnology progress.

[10]  Ashraf Amanullah,et al.  Automated dynamic fed‐batch process and media optimization for high productivity cell culture process development , 2013, Biotechnology and bioengineering.

[11]  Feng Li,et al.  Cell culture processes for monoclonal antibody production , 2010, mAbs.

[12]  L. Chasin,et al.  Amplified dihydrofolate reductase genes are localized to a homogeneously staining region of a single chromosome in a methotrexate-resistant Chinese hamster ovary cell line. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Scott Estes,et al.  Mammalian cell line developments in speed and efficiency. , 2014, Advances in biochemical engineering/biotechnology.

[14]  Thomas Ryll,et al.  Maximizing productivity of CHO cell‐based fed‐batch culture using chemically defined media conditions and typical manufacturing equipment , 2010, Biotechnology progress.

[15]  P. Sharp,et al.  Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary dna gene. , 1982, Journal of molecular biology.

[16]  S. J. Wilkinson,et al.  Model‐directed engineering of “difficult‐to‐express” monoclonal antibody production by Chinese hamster ovary cells , 2014, Biotechnology and bioengineering.

[17]  Natarajan Vijayasankaran,et al.  Understanding the intracellular effect of enhanced nutrient feeding toward high titer antibody production process , 2011, Biotechnology and bioengineering.

[18]  T. Mano,et al.  Overexpression of CHOP alone and in combination with chaperones is effective in improving antibody production in mammalian cells , 2012, Applied Microbiology and Biotechnology.

[19]  M. Brigido,et al.  Comparison of Humanized IgG and FvFc Anti-CD3 Monoclonal Antibodies Expressed in CHO Cells , 2010, Molecular biotechnology.

[20]  S. Sharfstein,et al.  Regulation of Recombinant Monoclonal Antibody Production in Chinese Hamster Ovary Cells: A Comparative Study of Gene Copy Number, mRNA Level, and Protein Expression , 2006, Biotechnology progress.

[21]  A. Ambrogelly,et al.  Assessment of AMBRTM as a model for high-throughput cell culture process development strategy , 2012 .

[22]  N. Mermod,et al.  CHO cell engineering to prevent polypeptide aggregation and improve therapeutic protein secretion. , 2014, Metabolic engineering.

[23]  Martin Gawlitzek,et al.  Development and implementation of a global Roche cell culture platform for production of monoclonal antibodies , 2013, BMC Proceedings.

[24]  Mareike Harmsen,et al.  Evaluation of the advanced micro-scale bioreactor (ambr™) as a highthroughput tool for cell culture process development , 2013, BMC Proceedings.

[25]  A. Varki,et al.  Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins , 2010, Nature Biotechnology.

[26]  Christopher Miller,et al.  High‐throughput miniaturized bioreactors for cell culture process development: Reproducibility, scalability, and control , 2014, Biotechnology progress.

[27]  D. Drapeau,et al.  Adaptation of mammalian cells to growth in serum-free media , 2000, Molecular biotechnology.

[28]  T. Ryll,et al.  Controlling trisulfide modification in recombinant monoclonal antibody produced in fed‐batch cell culture , 2012, Biotechnology and bioengineering.

[29]  T. Puck,et al.  GENETICS OF SOMATIC MAMMALIAN CELLS : II. CHROMOSOMAL CONSTITUTION OF CELLS IN TISSUE CULTURE , 1958 .

[30]  Renate Kunert,et al.  Benchmarking of commercially available CHO cell culture media for antibody production , 2015, Applied Microbiology and Biotechnology.

[31]  B. Snedecor,et al.  Chinese hamster ovary K1 host cell enables stable cell line development for antibody molecules which are difficult to express in DUXB11‐derived dihydrofolate reductase deficient host cell , 2013, Biotechnology progress.

[32]  K. Anumula Rapid quantitative determination of sialic acids in glycoproteins by high-performance liquid chromatography with a sensitive fluorescence detection. , 1995, Analytical biochemistry.

[33]  Nimish Dalal,et al.  Cell culture process operations for recombinant protein production. , 2014, Advances in biochemical engineering/biotechnology.

[34]  T. Ryll,et al.  Investigation of metabolic variability observed in extended fed batch cell culture , 2013, Biotechnology progress.

[35]  W. Hsu,et al.  Advanced microscale bioreactor system: a representative scale-down model for bench-top bioreactors , 2012, Cytotechnology.

[36]  H. Ohtake,et al.  Improved production of recombinant human antithrombin III in Chinese hamster ovary cells by ATF4 overexpression , 2008, Biotechnology and bioengineering.

[37]  Gyun Min Lee,et al.  CHO cells in biotechnology for production of recombinant proteins: current state and further potential , 2012, Applied Microbiology and Biotechnology.